Global Myocardial Infarction Drugs Market 2016-2020
About Myocardial Infarction Drugs
Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.
Technavio’s analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Myocardial Infarction Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Myocardial Infarction Drugs Market: AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, and Sanofi.
Other Prominent Vendors in the market are: advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, and Ventrix.
Commenting on the report, an analyst from Technavio’s team said: “Enhanced patient awareness is expected to lead to early disease diagnosis and treatment. The World Heart Federation along with Bupa, MOVEWeek, the European Healthy Stadia Network, and Days of the Year organizes 29th September of every year as the World Heart Day. Heart Day campaigns are organized to spread awareness about heart diseases. These campaigns are sponsored by Amgen, AstraZeneca, Bupa, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, and Unilever.”
According to the report, in older people, plaque accumulation in the arteries increases because of the loss of elasticity of the blood vessels. Drugmakers are realizing that an aging population will have significant impact on their business. Increasing number of patients plus lucrative pricing equals big growth for the market.
Further, the report states that the availability of effective surgical treatments and the use of catheter-based interventions pose a challenge to the growth of the market.
AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, Sanofi, advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, Ventrix.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook